AI summary · may contain errors
Mezigdomide treatment of ex vivo generated exhausted T cells in multiple myeloma is linked to decreased exhaustion-marker expression and increased proinflammatory cytokine expression.
- 1 cited this week
- Open access
Moving in Blood.
Rebuilt
AI summary · may contain errors
Mezigdomide treatment of ex vivo generated exhausted T cells in multiple myeloma is linked to decreased exhaustion-marker expression and increased proinflammatory cytokine expression.
Newest first · last 60 days
AI summary · may contain errors
WY6 disrupts p300–ZEB1 binding and suppresses K80 acetylation, leading to reduced ZEB1 stability and tumor growth suppression in an orthotopic in vivo model.
AI summary · may contain errors
P2RX5-FL is expressed by up to 75% of individuals with African ancestry and is stable on the plasma membrane, enabling CAR T targeting.
AI summary · may contain errors
Antibody-conjugated CCNK molecular glue degrader Tz-SS2009 drives ubiquitin-proteasome–dependent CCNK degradation and stronger antiproliferative effects in HER2-positive breast cancer cells than HER2-negative cells.
AI summary · may contain errors
ProLigGPT, a GPT-2–based seq2seq language model trained on ~1.9 million protein–ligand pairs without 3D structures, achieves superior ligand-design performance across eight target proteins.
AI summary · may contain errors
AML874, a selective CDK8/CDK19 inhibitor, disrupts Mediator-dependent transcription and shows subtype-specific sensitivity in FLT3-mutated AML, with strong synergy to venetoclax.
AI summary · may contain errors
ALP-1, a targeted monovalent ULK1 degrader chemical tool, controls ULK1 abundance and engages ULK1 via an atypical chloroacetamide–aspartate conjugation at the ATP-binding site.
AI summary · may contain errors
HQY1428, a cyclin K molecular glue degrader, promotes CDK12–DDB1 association and rapid cyclin K degradation, depleting CDK12 condensates at nuclear speckles.
AI summary · may contain errors
PROTAC-mediated degradation of tankyrase (TNKS) overcomes AXIN puncta–driven resistance that limits catalytic TNKS inhibitors, enabling deeper WNT/β-catenin suppression in colorectal cancer cells with dysfunctional APC mutations.
AI summary · may contain errors
S-023-0996 (41a) is a tumor cell-selective dual EZH2-EGFR inhibitor that more efficiently suppresses TNBC tumor growth and metastasis in preclinical models than EZH2+EGFR drug combinations.
AI summary · may contain errors
Deubiquitinases (DUBs) are positioned as key regulators at the interface of T-cell immunity and tumor-intrinsic immune evasion, shaping ubiquitin signaling that affects both compartments.
AI summary · may contain errors
GenSci143, a B7-H3 × PSMA-directed bispecific antibody-drug conjugate, produced profound tumor regression in prostate cancer xenograft models and showed superior antitumor activity versus competitor ADCs.
AI summary · may contain errors
In vivo CAR T-cell therapy in relapsed or refractory multiple myeloma is linked to deep responses and measurable residual disease negativity after BCMA-directed treatment, with durability shaped by host context.
AI summary · may contain errors
CDK8 inhibitors, including a novel pyridyl imidazole, impair the EWSR1::FLI1 transcriptional program in Ewing sarcoma cells by inducing Mediator trapping on chromatin.
AI summary · may contain errors
At least 75 covalent drugs have gained regulatory approval, including therapies for KRAS G12C, EGFR L858R, T790M, and BTK, showing broad clinical reach.
AI summary · may contain errors
DPB is a covalent molecular glue that selectively kills p53-deficient NSCLC by recruiting RPS7 to MKRN2, enabling RPS7 ubiquitination and proteasomal degradation.
AI summary · may contain errors
Reversible covalent modulators that target non-cysteine nucleophiles—especially serine and lysine—are emerging as a promising way to modulate protein-protein interactions with sustained engagement and selectivity.
AI summary · may contain errors
Non-cysteine covalent inhibitors targeting lysine, serine, tyrosine, threonine, and histidine are increasingly explored to expand covalent drug discovery beyond cysteine dominance.
AI summary · may contain errors
Covalent chemoproteomics and structural data identified ligandable cysteines, tyrosines, and lysines on interferonopathy-associated proteins, including ligandable sites on ADAR1, RNASEH2A, and SAMHD1.
AI summary · may contain errors
Single-molecule genomics enables genome-wide profiling of regulatory factor activity on individual DNA molecules, quantifying heterogeneity and co-occurrence of events.
AI summary · may contain errors
Selective covalent binders increase protein thermal stabilisation in five model targets, but non-selective irreversible binding is typically neutral or destabilising, separating covalent bond effects from reactivity.
AI summary · may contain errors
AI-designed 80-amino-acid minibinders targeting human CD20 in CAR T cells yielded 707 CD20-specific enriched designs out of 12,000 submissions, with team hit rates up to 38.4%.
Journals this month
Topics moving, week to 17 Nov 2026
By field